Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

计划入组 30 人 · 首次发布于 2021 年 9 月 22 日

BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.

计划入组 206 人 · 首次发布于 2024 年 9 月 19 日

Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

计划入组 17 人 · 首次发布于 2019 年 4 月 3 日

gossypol derivatives (INSERM)

Bcl-2 inhibitors (cancer)

BCL-2 protein inhibitors (cancer)

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

Acalabrutinib Plus Venetoclax Significantly Improves PFS in Untreated CLL

Ascentage Pharma's Lisaftoclax Receives Priority Review in China for Relapsed/Refractory CLL/SLL

China's NMPA Accepts Ascentage Pharma's NDA for Lisaftoclax in R/R CLL/SLL with Priority Review